Stay updated with breaking news from Beigene agreement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results News provided by Share this article Share this article CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020. 2020 Leap Highlights: Signed agreement with BeiGene, Ltd. for rights to Leap s anti-DKK1 antibody, DKN-01, in Asia (excluding Japan), Australia and New Zealand Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock Presented updated data from study of DKN-01 plus pembrolizumab in esophagogastric (EGC) cancer demonstrating positive outcomes in DKK1-high patients ....